Viva Biotech Holdings announced a further contraction of its share base following the cancellation of 25.32 million previously repurchased shares on 22 June 2026. The cancellation represents 1.19 % of the company’s issued share capital prior to the event and lowers the total number of issued shares (excluding treasury shares) to 2.10 billion, down from 2.13 billion as at 18 June 2026.

In parallel, the company reported 4.99 million additional shares repurchased between 8 June and 22 June 2026 that remained uncancelled at the statement date. These shares, equal to 0.23 % of the current share base, were acquired at a volume-weighted average price of HKD 1.14 per share, implying an aggregate consideration of approximately HKD 5.71 million.

Key transaction details • Cancelled tranche: 25.32 million shares bought back from 8 May to 5 June 2026 at an average price of HKD 1.39, officially cancelled on 22 June 2026. • Latest on-market purchase: 510,000 shares on 22 June 2026 at HKD 1.10 each, totalling HKD 0.56 million. • Cumulative buy-backs under the current mandate (granted on 12 June 2025) have reached 30.30 million shares, equal to 1.42 % of the shares outstanding on the mandate date.

Post-transaction share capital structure • Issued shares (excluding treasury shares): 2.10 billion. • Treasury shares: none. • Remaining capacity under the 212.84 million-share repurchase mandate: 182.54 million shares.

Pursuant to Hong Kong Stock Exchange rules, Viva Biotech is restricted from issuing new shares or transferring any treasury shares until 22 July 2026.

The company confirmed that all repurchase activities were executed on the Hong Kong Stock Exchange in compliance with the Exchange’s Main Board Listing Rules and relevant regulatory requirements.